2024 CSCO Guideline Symposium: Professor Tiejun Gong: “Updates to the CSCO Guidelines for Malignant Hematologic Diseases” Drive Clinical Diagnosis

2024 CSCO Guideline Symposium: Professor Tiejun Gong: “Updates to the CSCO Guidelines for Malignant Hematologic Diseases” Drive Clinical Diagnosis

2024.05.08
With the development of targeted therapy and immunotherapy, the treatment options for malignant hematologic diseases continue to expand. The "Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Malignant Hematologic Diseases (2024)" has once again been updated. "Oncology Watch" specially interviewed one of the guideline's authors, Professor Tiejun Gong from the Harbin Institute of Hematology and Oncology, to provide in-depth explanations on the highlights of the guideline updates, their impact on clinical practice, and the implementation of the guidelines.
Professor Qing Cao’s Commentary: Emerging Staphylococcus Threatens Newborn Health | ESCMID Global 2024

Professor Qing Cao’s Commentary: Emerging Staphylococcus Threatens Newborn Health | ESCMID Global 2024

2024.05.08
In low- and middle-income countries, the health of newborns faces numerous challenges, with neonatal sepsis being a particularly grave concern. At the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024), a study (abstract number: O0158) focused on the threat posed by Coagulase-Negative Staphylococci (CoNS) to newborn health. These bacteria, increasingly reported in low- and middle-income countries, exhibit insensitivity to multiple commonly used antibiotics, complicating treatment. Professor Qing Cao from the Shanghai Children's Medical Center, affiliated with Shanghai Jiao Tong University School of Medicine, provides a detailed commentary on this study, sharing her professional insights and recommendations.
EBMT Distinguished Interview | Optimizing Induction Therapy Before ASCT: From Past to Future

EBMT Distinguished Interview | Optimizing Induction Therapy Before ASCT: From Past to Future

2024.05.08
Induction therapies with high remission rates, combined with high-dose chemotherapy and autologous stem cell transplantation (ASCT), have significantly improved the prognosis for multiple myeloma (MM) patients. Despite this, patients still inevitably experience disease progression or relapse. One of the key goals in this research field is how to maintain remission in patients after induction therapy and ASCT. The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting took place in Glasgow, UK, from April 14 to 17, 2024. The conference focused on the latest advancements in stem cell transplantation and cellular therapy, driving better clinical outcomes for patients with hematological diseases and cancers. At this conference, Professor Jean-Luc Harousseau, Chairman of the French National Health Authority and Director of the René Gauducheau Cancer Center at the University of Nantes, delivered an insightful presentation on optimizing induction therapy strategies for multiple myeloma patients before ASCT. "Hematology Frontier" invited Professor Harousseau to share his insights on continuously optimizing pre-ASCT induction therapy for multiple myeloma patients.
Professor Wei Yu Shares Research Progress in NMIBC Treatment | EAU24 Expert Commentary

Professor Wei Yu Shares Research Progress in NMIBC Treatment | EAU24 Expert Commentary

2024.05.07
Transurethral resection of bladder tumors (TURBt) is the conventional treatment for non-muscle-invasive bladder cancer (NMIBC). Patients are stratified into low, intermediate, high, and very high risk categories, with different postoperative bladder instillation treatments and follow-up monitoring strategies for different risk patients. Several advancements in NMIBC research were presented at the recent EAU conference, and "Oncology Frontier-Urology Frontier" invited Professor Wei Yu from Peking University First Hospital to share related research findings.
 Recent Advances in the Treatment of Advanced Urothelial Carcinoma: Insights from Dr. Jens Bedke

 Recent Advances in the Treatment of Advanced Urothelial Carcinoma: Insights from Dr. Jens Bedke

2024.05.07
Platinum-based combination chemotherapy remains the cornerstone of treatment for advanced urothelial carcinoma (UC), but it still falls short of meeting long-term survival needs. At the 39th Annual Congress of the European Association of Urology (EAU24) held in Paris, France, Dr. Jens Bedke, from Klinikum Stuttgart Katharinen Hospital, shared the results of the EV-302/KEYNOTE-A39 study. Urology Frontier had the privilege of inviting renowned expert Dr. Jens Bedke to discuss the current status of immunotherapy, recent major advances in clinical trials, and future directions in UC treatment.
Professor Vasileios Sakalis on the Value of Artificial Intelligence in the Diagnosis and Treatment of Urological Tumors

Professor Vasileios Sakalis on the Value of Artificial Intelligence in the Diagnosis and Treatment of Urological Tumors

2024.05.07
Artificial Intelligence (AI) is transforming the diagnostic and treatment approaches for urological tumors, especially with significant advancements in intelligent imaging and pathology, potentially becoming an indispensable tool for clinicians. Dr. Vasileios Sakalis, a urologist from the Hippokrateion General Hospital of Thessaloniki, Greece, presented a comprehensive review on the application of AI in urological tumors at the conference. During an on-site interview with "Oncology Frontier-Urology Frontier," he shared further insights on the applications of AI.
2024 CUDA Yanqi Lake Conference | Professor Xiongjun Ye Shares Recent Breakthroughs in Renal Cell Carcinoma Treatment

2024 CUDA Yanqi Lake Conference | Professor Xiongjun Ye Shares Recent Breakthroughs in Renal Cell Carcinoma Treatment

2024.05.07
The ASCO-GU, a premier academic conference in urologic oncology, at the beginning of the year sparked academic enthusiasm in 2024, receiving over 140 abstracts related to renal cell carcinoma (RCC). Professor Xiongjun Ye from the Chinese Academy of Medical Sciences Cancer Hospital presented a report on the significant progress in RCC treatment from the ASCO-GU at the 4th Yanqi Lake Conference of the Chinese Medical Association Urology Surgery Branch, summarizing the essence for all to appreciate.
2024CUDA Conference | Professor Benkang Shi: Focus on Unmet Needs of mHSPC Patients, Achieve Stratified Treatment for Key Populations

2024CUDA Conference | Professor Benkang Shi: Focus on Unmet Needs of mHSPC Patients, Achieve Stratified Treatment for Key Populations

2024.05.06
The current treatment status of mHSPC patients in China and the need for further improvement have drawn attention. Recently, at the "4th Annual Conference of the Urology Physicians Branch of the Chinese Medical Association (2024)" held in Beijing, Professor Benkang Shi from Qilu Hospital of Shandong University shared insights on "Long-term Management of mHSPC Patients with Novel Hormonal Therapy Schemes." Following the conference, "Oncology Frontier - Urology News" invited Professor Benkang Shi to share insights on the diagnosis and treatment status of mHSPC, stratification of key populations, and personalized treatment
2024CUDA Conference | Professor Qiang Wei: Early Initiation of Novel Hormonal Therapy Brings More Benefits to Patients

2024CUDA Conference | Professor Qiang Wei: Early Initiation of Novel Hormonal Therapy Brings More Benefits to Patients

2024.05.06
The "4th Annual Conference of the Urology Physicians Branch of the Chinese Medical Association (2024)" was successfully held in Beijing from April 13th to 14th. During the conference, Professor Qiang Wei from West China Hospital, Sichuan University, shared insights on "Standard Treatment of mHSPC in the Era of Novel Hormonal Therapy." Subsequently, "Oncology Frontier - Urology News" invited Professor Qiang Wei to discuss the significance of early initiation of novel hormonal therapy for mHSPC patients, the comparison between dual and triple therapy, and precise treatment selection strategies.
BISC 2024丨Professor Junyan Qu: Interpretation of Anthrax Diagnosis and Treatment Plan (2023 Edition)

BISC 2024丨Professor Junyan Qu: Interpretation of Anthrax Diagnosis and Treatment Plan (2023 Edition)

2024.05.03
Anthrax is a zoonotic infectious disease caused by Bacillus anthracis infection, which still occurs sporadically in some areas of China. Anthrax can manifest in various clinical forms, with pulmonary anthrax having a mortality rate of over 80% and requiring management as a Class A infectious disease. In order to further standardize the clinical diagnosis and treatment of anthrax, the National Health Commission issued the "Anthrax Diagnosis and Treatment Plan (2023 Edition)." At the recent Fourth National Congress of the Chinese Society of Infectious Diseases (BISC 2024), Professor Junyan Qu, the secretary-general of the conference and from the Infectious Diseases Center of West China Hospital, Sichuan University, interpreted the diagnosis and treatment plan based on case studies. The summary is presented below.